JPS6141915B2 - - Google Patents
Info
- Publication number
- JPS6141915B2 JPS6141915B2 JP7920777A JP7920777A JPS6141915B2 JP S6141915 B2 JPS6141915 B2 JP S6141915B2 JP 7920777 A JP7920777 A JP 7920777A JP 7920777 A JP7920777 A JP 7920777A JP S6141915 B2 JPS6141915 B2 JP S6141915B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- dihydro
- represented
- triazine derivative
- lower alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 10
- 125000002947 alkylene group Chemical group 0.000 claims description 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 150000001875 compounds Chemical class 0.000 description 23
- 238000010992 reflux Methods 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- -1 3-methyl-5-isoxazolylethyl Chemical group 0.000 description 12
- 230000000694 effects Effects 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 238000000921 elemental analysis Methods 0.000 description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- MIWVBVPUEOHJFV-UHFFFAOYSA-N [amino(azaniumylidene)methyl]-(diaminomethylidene)azanium;sulfate Chemical compound OS(O)(=O)=O.NC(N)=NC(N)=N MIWVBVPUEOHJFV-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229940123208 Biguanide Drugs 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 235000021588 free fatty acids Nutrition 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- MTDCOVMWFRISHZ-UHFFFAOYSA-N 1-(3-methyl-1,2-oxazol-5-yl)butan-2-one Chemical compound CCC(=O)CC1=CC(C)=NO1 MTDCOVMWFRISHZ-UHFFFAOYSA-N 0.000 description 2
- YSUCWSWKRIOILX-UHFFFAOYSA-N 1-(diaminomethylidene)-2-(2-phenylethyl)guanidine;hydrochloride Chemical compound Cl.NC(N)=NC(N)=NCCC1=CC=CC=C1 YSUCWSWKRIOILX-UHFFFAOYSA-N 0.000 description 2
- GPWNWKWQOLEVEQ-UHFFFAOYSA-N 2,4-diaminopyrimidine-5-carbaldehyde Chemical compound NC1=NC=C(C=O)C(N)=N1 GPWNWKWQOLEVEQ-UHFFFAOYSA-N 0.000 description 2
- GEWPFPUABRRBPS-UHFFFAOYSA-N 3-methyl-1,2-oxazole-5-carbaldehyde Chemical compound CC=1C=C(C=O)ON=1 GEWPFPUABRRBPS-UHFFFAOYSA-N 0.000 description 2
- OCOCVXUEFWNRJU-UHFFFAOYSA-N 5-methyl-1,2-oxazole-3-carbaldehyde Chemical compound CC1=CC(C=O)=NO1 OCOCVXUEFWNRJU-UHFFFAOYSA-N 0.000 description 2
- CZAZDIRRZHGKBI-UHFFFAOYSA-N 5-methyl-1h-pyrazole-3-carbaldehyde Chemical compound CC=1C=C(C=O)NN=1 CZAZDIRRZHGKBI-UHFFFAOYSA-N 0.000 description 2
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 125000004344 phenylpropyl group Chemical group 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- HTTOWFIYAYYAQD-UHFFFAOYSA-N 1-(5-methyl-1,2-oxazol-3-yl)propan-1-one Chemical compound CCC(=O)C=1C=C(C)ON=1 HTTOWFIYAYYAQD-UHFFFAOYSA-N 0.000 description 1
- XWFPIJRFFLYWRN-UHFFFAOYSA-N 1-(diaminomethylidene)-2-ethylguanidine Chemical compound CCN=C(N)N=C(N)N XWFPIJRFFLYWRN-UHFFFAOYSA-N 0.000 description 1
- FAPXKQMFIRYKMF-UHFFFAOYSA-N 1-(diaminomethylidene)-2-propylguanidine Chemical compound CCCN=C(N)N=C(N)N FAPXKQMFIRYKMF-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxane Natural products O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229960004111 buformin Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7920777A JPS5414986A (en) | 1977-07-01 | 1977-07-01 | Production of dihydrooss triazine derivative |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7920777A JPS5414986A (en) | 1977-07-01 | 1977-07-01 | Production of dihydrooss triazine derivative |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS5414986A JPS5414986A (en) | 1979-02-03 |
JPS6141915B2 true JPS6141915B2 (pt) | 1986-09-18 |
Family
ID=13683490
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP7920777A Granted JPS5414986A (en) | 1977-07-01 | 1977-07-01 | Production of dihydrooss triazine derivative |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS5414986A (pt) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1250328B2 (fr) † | 2000-01-26 | 2010-04-21 | Merck Sante | Derives amines de dihydro-1,3,5-triazine et leurs applications en therapeutique |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5677477A (en) * | 1979-11-28 | 1981-06-25 | Shin Meiwa Ind Co Ltd | Locking device for doubleeleafed hinged door in freight box of car |
AU2003231538A1 (en) * | 2002-05-17 | 2003-12-02 | Kyowa Hakko Kogyo Co., Ltd. | Method of searching substane having antidiabetic activity |
FR2853650B1 (fr) * | 2003-04-10 | 2006-07-07 | Merck Sante Sas | Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance |
DE102007054416A1 (de) | 2007-11-13 | 2009-05-14 | Studiengesellschaft Kohle Mbh | Verfahren zur Herstellung von 3,6-Dihydro-1,3,5- Triazin-Derivaten für die Behandlungen von Erkrankungen, die mit dem Insulinresistenz-Syndrom assoziiert sind |
-
1977
- 1977-07-01 JP JP7920777A patent/JPS5414986A/ja active Granted
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1250328B2 (fr) † | 2000-01-26 | 2010-04-21 | Merck Sante | Derives amines de dihydro-1,3,5-triazine et leurs applications en therapeutique |
Also Published As
Publication number | Publication date |
---|---|
JPS5414986A (en) | 1979-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1262248A (en) | Tertiary hydroxyalkylxanthines, processes for their preparation, medicaments containing them and their use | |
US4289776A (en) | Xanthine derivatives | |
EP1309594B1 (fr) | Derives de benzimidazole, leur preparation et leur application en therapeutique | |
JPS626546B2 (pt) | ||
CA2095587C (en) | Process for preparing aryl piperazinyl-hetero-cyclic compounds | |
EP0103497B1 (fr) | Nouveaux dérivés de la xanthine, leur procédé de préparation et les compositions pharmaceutiques les renfermant | |
US4201860A (en) | Purine derivatives | |
JPS623153B2 (pt) | ||
US4108995A (en) | Hydroxyhexyl-alkylxanthines and pharmaceutical compositions containing hydroxyhexyl-alkylxanthines | |
JPS6141915B2 (pt) | ||
SU1340585A3 (ru) | Способ получени производных тетразола | |
Baltzly et al. | Amines Related to 2, 5-Dimethoxyphenethylamine. 1 I | |
JPH0436156B2 (pt) | ||
JPS6183163A (ja) | 抗腫瘍剤 | |
JPS6251672A (ja) | 新規な2−(4−フエニル−1−ピペラジニルアルキル)アミノピリミジン誘導体及びその酸付加塩 | |
JPH0625191B2 (ja) | 1−[2−(フエニルメチル)フエニルピペラジン化合物、その製造方法および医薬組成物 | |
JPH0361672B2 (pt) | ||
JPS6148516B2 (pt) | ||
CA1075690A (en) | Xanthine derivatives | |
WO1990002552A1 (en) | Antipsychotic 4-[4-(3-benzisothiazolyl)-1-piperazinyl]butyl bridged bicyclic imides | |
JPH0559107B2 (pt) | ||
CA1050543A (en) | Process for the preparation of 2-acylamino-benzylamines | |
JP2539261B2 (ja) | イミダゾ―ル誘導体 | |
JPS6147834B2 (pt) | ||
JPS6257620B2 (pt) |